Targeting the interaction between the kidneys and brain may increase the efficiency of SGLT2 inhibitors to better manage type 2 diabetes.

SGLT2 inhibitors reduce podocyte lipotoxicity and improve kidney function in experimental Alport syndrome through a mechanism that involves a switch from the utilization of glucose to fatty acids as an energy substrate in podocytes.

Anti-asprosin monoclonal antibodies, a promising pharmacotherapy for the treatment of metabolic syndrome-associated hyperglycemia, obesity, and dyslipidemia.

We are writing to comment on the study by Meyer et al., 2016 on disease-ameliorating autoantibodies.

Monounsaturated fatty acids protect against DKD by enhancing membrane fluidity and decreasing ER lipid bilayer stress in renal proximal tubules.

Gut microbiota can influence mPFC transcriptional profiles and myelin content, overriding the impact of genetic background in the development of social avoidance behavior.

Eugenol has the ability to improve the type 1 diabetes mellitus through NRF2-mediated oxidative stress pathway.

mTORC1 inhibition by perinatal ER stress induces beta-cell growth arrest with subsequent development of diabetes.